MiTMAB

**MiTMAB** is a small-molecule inhibitor of dynamin, a GTPase critical for membrane fission during endocytosis and cytokinesis. It selectively disrupts the dynamin-phospholipid interaction, inhibiting dynamin GTPase activity with a **Ki of 940 nM**, thereby blocking receptor-mediated endocytosis (e.g., transferrin and EGF uptake), synaptic vesicle endocytosis, and the abscission phase of cytokinesis, leading to polyploidization. In cancer cells, MiTMAB induces caspase-mediated apoptosis via the intrinsic pathway following cytokinesis failure, with selectivity for cells expressing low levels of anti-apoptotic proteins like Bcl-2. It has also been used experimentally to enhance intracellular protoporphyrin IX (PpIX) accumulation by inhibiting dynamin-dependent exocytosis, potentially augmenting photodynamic therapy efficacy.

Other names

Myristyltrimethylammonium bromideMTABTTABTetradecyltrimethylammonium bromide